AVITA Medical Appoints Joe Woody as Board Director, Lou Panaccio Retires

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: Jan 05 2026

0mins

RCEL-0.76%

Should l Buy RCEL?

Source: Globenewswire

New Board Appointment: AVITA Medical announces the appointment of Joe Woody as a new non-executive director, bringing over 20 years of leadership experience in the med-tech sector, which will be crucial for the company's growth trajectory.
Leadership Transition: Lou Panaccio retires after over a decade of service, having served as Chairman and significantly shaped the company's commercial and operational strategies, ensuring stability in the market.
Rich Industry Experience: Joe Woody's previous roles include CEO of Avanos Medical and executive positions at Acelity Holdings, enhancing the board's depth of expertise with his extensive background in the industry.
Strategic Value Enhancement: The addition of the new director not only strengthens AVITA Medical's leadership team but also supports the company's innovation and market expansion in acute wound care solutions.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy RCEL?" and start using high-conviction signals backed by rigorous historical data.

RCEL

$3.9+Infinity%1D

Analyst Views on RCEL

Wall Street analysts forecast RCEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RCEL is 4.25 USD with a low forecast of 3.00 USD and a high forecast of 5.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Analyst Rating

1 Buy

2 Hold

0 Sell

Moderate Buy

Current: 3.930

Low

3.00

Averages

4.25

High

5.50

Current: 3.930

Low

3.00

Averages

4.25

High

5.50

Lake Street

Hold

maintain

2026-01-16

Reason

Lake Street

Price Target

AI Analysis

2026-01-16

maintain

Hold

Reason

Lake Street raised the firm's price target on Avita Medical to $3.50 from $3 and keeps a Hold rating on the shares. Debt refinancing was "a necessary step to remove near-term liquidity concerns," says the analyst, who thinks full Q4 results and commentary around reimbursement trends could provide incremental confidence into the outlook, but stays at Hold as the firm waits to see business stabilization.

BTIG

Sell -> Neutral

upgrade

2025-11-20

Reason

BTIG

Price Target

2025-11-20

upgrade

Sell -> Neutral

Reason

BTIG upgraded Avita Medical to Neutral from Sell with no price target following Q3 results and the CEO change that occurred as a result. Shares are down about 71% year-to-date and the firm thinks the company's "wounds are starting to heal or at least cannot get materially much worse," the analyst tells investors. While the firm shares are not quite at a place where it can recommend them, it adds that it is not inclined to recommend selling anymore either.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RCEL

Unlock Now

About RCEL

AVITA Medical, Inc. is a therapeutic acute wound care company. The Company’s technologies optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of its platform is the RECELL System for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin Cells, offering a solution for improved clinical outcomes at the point-of-care. In the United States, it also holds the exclusive rights to market, sell, and distribute Cohealyx, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix. Its technologies are designed to optimize skin restoration procedures, effectively accelerating patient healing and recovery. Its solutions improve the healing outcomes for patients with traumatic injuries and surgical repairs, addressing critical healing needs that arise from unpredictable and life-changing events.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Bragar Eagel & Squire Investigates Soleno, Avita, and Coty for Potential Securities Violations

Jan 08 2026Globenewswire

Soleno Stock Decline: Following a report from Scorpion Capital labeling Soleno Therapeutics' Vykat XR as overpriced and potentially unsafe for children, the stock plummeted by 7.41% to close at $71.63 on August 15, 2025, indicating significant market concerns regarding product safety.
Avita Financial Struggles: Avita Medical revealed a backlog of unpaid claims affecting demand for its Recell product in its Q2 2025 report, leading to a 21% drop in stock price to $4.25 on August 8, 2025, highlighting major challenges in medical claims management.
Coty's Disappointing Performance: Coty reported an unexpected loss and provided disappointing guidance for FY 2025, resulting in a 21.6% decline in stock price to $3.81 on August 21, 2025, reflecting broader market challenges and shifts in consumer behavior impacting sales.
Legal Investigation Impact: Bragar Eagel & Squire is investigating potential federal securities law violations by these three companies, which could lead to further legal and financial repercussions, necessitating investor vigilance regarding future developments to assess potential risks.